Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	<0.001
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001
Age	41-55 years vs. ≤ 40 years	0.63 (0.49-0.81)	<0.001
Tumor size	Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm)	1.80 (1.33-2.45)	<0.001
	Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm)	1.86 (1.26-2.74)
Grade	Unknown vs. poor	0.83 (0.61-1.11)	0.08
	Well/moderate vs. poor	0.69 (0.49-0.98)

* Analyses stratified for hormone receptor status, nodal status and RT on the axilla. All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.